Effect of Trimetazidine on Recurrent Angina Pectoris and Left Ventricular Structure in Elderly Multivessel Coronary Heart Disease Patients with Diabetes Mellitus After Drug-Eluting Stent Implantation: A Single-Centre, Prospective, Randomized, Double-Blin
详细信息 查看全文
- 作者：Xiaohan Xu (1)
Weijun Zhang (1)
Yujie Zhou (1)
Yingxin Zhao (1)
Yuyang Liu (1)
Dongmei Shi (1)
Zhiming Zhou (1)
Hanying Ma (1)
Zhijian Wang (1)
Miao Yu (1)
Qian Ma (1)
Fei Gao (1)
Hua Shen (1)
Jianwei Zhang (1) - 刊名：Clinical Drug Investigation
- 出版年：2014
- 出版时间：April 2014
- 年：2014
- 卷：34
- 期：4
- 页码：251-258
- 全文大小：543 KB
- 参考文献：1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-3. CrossRef
2. Danchin N, Marzilli M, Parkhomenko O, et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology. 2011;120:59-2. CrossRef
3. Hanania G, Cambou JP, Guéret P, et al. Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart. 2004;90:1404-0. CrossRef
4. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA. 2003;289:1117-3. ma.289.9.1117" target="_blank" title="It opens in new window">CrossRef
5. Hueb W, Soares PR, Gersh BJ, et al. The Medicine, Angioplasty, or Surgery trial (MASS-II): a randomized, controlled, clinical trial of three therapeutic strategies for multivessel coronary artery disease. One-year results. J Am Coll Cardiol. 2004;43:1743-1. CrossRef
6. Gersh BJ. Coronary revascularization for angina pectoris in the elderly. Rev Cardiovasc Med. 2003;4:55-.
7. Hu B, Li W, Xu T, et al. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials. Clin Cardiol. 2011;34:395-00. CrossRef
8. Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97:278-6. CrossRef
9. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-03. CrossRef
10. Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59:913-2. CrossRef
11. Fragasso G, Rosano G, Baek SH, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol. 2013;163:320-. CrossRef
12. Henderson RA, Pocock SJ, Clayton TC, et al. Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical treatment. J Am Coll Cardiol. 2003;42:1161-0. CrossRef
13. Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina—the VASCO-angina study. Int J Cardiol. 2013;168:1078-1. CrossRef
14. Bucci M, Borra R, N?gren K, et al. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther. 2012;30:333-1. CrossRef
15. Fragasso G, Salerno A, Lattuada G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart. 2011;97:1495-00. CrossRef
16. Zhou X, Li C, Xu W, et al. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS One. 2012;7:e40424. CrossRef
17. Wu Q, Qi B, Liu Y, et al. Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against H2O2-induced injury: involvement of antioxidation and Akt/eNOS signaling pathways. Eur J Pharmacol. 2013;707:87-4. CrossRef
18. Dehina L, Vaillant F, Tabib A, et al. Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:205-5. CrossRef
19. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25:1814-1. CrossRef
20. Zhao P, Zhang J, Yin XG, et al. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci. 2013;92:633-. CrossRef
21. Bonow RO. The hibernating myocardium: implications for management of congestive heart failure. Am J Cardiol. 1995;75:17A-5A. CrossRef
22. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2001;37:1042-. CrossRef - 作者单位：Xiaohan Xu (1)
Weijun Zhang (1)
Yujie Zhou (1)
Yingxin Zhao (1)
Yuyang Liu (1)
Dongmei Shi (1)
Zhiming Zhou (1)
Hanying Ma (1)
Zhijian Wang (1)
Miao Yu (1)
Qian Ma (1)
Fei Gao (1)
Hua Shen (1)
Jianwei Zhang (1)
1. Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University and Beijing Institute of Heart Lung and Blood Vessel Disease, Anzhenli Avenue, Chao Yang District, Beijing, 100029, China - ISSN：1179-1918
文摘
Background and Objective Trimetazidine has been shown to improve angina pectoris and left ventricular (LV) function in diabetic patients with ischaemic cardiomyopathy. The objective of this study was to evaluate the effects of trimetazidine on recurrent angina pectoris and LV structure after drug-eluting stent (DES) implantation in elderly multivessel coronary heart disease (CHD) patients with diabetes mellitus (DM) and a left ventricular ejection fraction (LVEF) of ?0?%. Methods This was a single-centre, prospective, randomized, double-blind evaluation study. Between January 2010 and September 2010, 700 CHD patients with DM who were aged ?5?years and undergoing coronary angiography at An Zhen Hospital (Beijing, China) were recruited and prospectively randomized to receive trimetazidine (20?mg three times daily) or placebo after DES implantation as an addition to conventional CHD treatment. The primary end points were the incidence of recurrent angina pectoris and measures of various echocardiographic parameters, which included LVEF. Results At 2-year follow-up, patients in the trimetazidine group (n?=?255) showed significant improvements in the incidence (P?=?0.024) and severity of angina pectoris, compared with the control group, as well as silent myocardial ischaemia (P?=?0.009) and angina pectoris-free survival (P?=?0.011). LV function and structure in trimetazidine-treated patients were relatively stable at 2-year follow-up, while they deteriorated in the control group (n?=?255) with a significant difference between groups (all P?<?0.01). The E peak to A peak (E/A) ratio in trimetazidine-treated patients and in the control group decreased after 2 years; the E/A ratio in trimetazidine-treated patients was slightly better than that in the control group, without a significant difference (P?=?0.170). There was no significant difference in event-free survival for the composite end point including death, myocardial infarction, cerebrovascular accident (P?=?0.422) and subsequent revascularization (P?=?0.073). Conclusion Adjunctive therapy with trimetazidine after DES implantation can have a beneficial effect on recurrent angina pectoris as well as LV function and structure in elderly multivessel CHD patients with DM.